Dianabol

Metandienone (International Nonproprietary Name), known commercially as Dianabol and chemically as 17-alpha-methyl-delta-1-testosterone, is a synthetic anabolic-androgenic steroid (AAS) of the androstane class first synthesized at CIBA Pharmaceuticals in Switzerland in the mid-1950s and introduced to the United States prescription market in 1958. The compound is a structural modification of testosterone bearing two critical alterations: a methyl group at the C17-alpha position that confers oral bioavailability by resisting hepatic first-pass metabolism, and a delta-1 (C1-C2) double bond that modifies the anabolic-to-androgenic activity ratio relative to the parent hormone. Metandienone binds the androgen receptor (AR) in skeletal muscle, prostate, and other androgen-responsive tissues, initiating genomic signaling cascades that increase protein synthesis, nitrogen retention, and glycogenolysis. The compound undergoes aromatization by the CYP19A1 (aromatase) enzyme to 17-alpha-methylestradiol, producing dose-dependent estrogenic effects including fluid retention and gynecomastia. Hepatic metabolism proceeds principally through CYP3A4-catalyzed 6-beta-hydroxylation, with additional pathways including 5-beta-reduction, 3-alpha and 3-beta oxidation, and 17-epimerization; the 17-alpha-alkylation that confers oral bioavailability simultaneously produces the hepatotoxicity characteristic of this structural class.

The compound was originally developed and marketed for the treatment of catabolic states, post-surgical recovery, osteoporosis, and hypogonadism. Clinical trials conducted in the late 1950s and 1960s demonstrated significant positive nitrogen balance at oral doses of 5 to 10 mg in the published literature, with measurable increases in lean body mass and appetite stimulation. However, escalating recognition of the hepatotoxic, cardiovascular, endocrine-suppressive, and estrogenic adverse-effect profile led to progressive restriction of approved indications, and the United States Food and Drug Administration withdrew approval in 1983. The compound is currently classified as a Schedule III controlled substance in the United States under the Controlled Substances Act and is prohibited by the World Anti-Doping Agency. It is not approved for any medical indication in any major regulatory jurisdiction.

Despite the absence of current clinical approval, metandienone remains a compound of substantial research interest. Its well-characterized androgen receptor pharmacology, its defined hepatotoxic mechanism as a model 17-alpha-alkylated steroid, its known metabolic pathways and urinary metabolite profile (exploited extensively in anti-doping analytical chemistry), and its historical clinical dataset in nitrogen-balance and muscle-wasting research provide a comprehensive pharmacological record. Preclinical studies in rat models have demonstrated that metandienone stimulates levator ani muscle hypertrophy through androgen receptor activation, suppresses the hypothalamic-pituitary-testicular axis, and modulates myostatin signaling pathways. This monograph reviews the chemistry, synthesis, and stereochemistry of metandienone; the androgen receptor pharmacology and mechanism of action; the comprehensive pharmacokinetic record including hepatic metabolism and urinary metabolite detection; the historical clinical evidence base; sourcing and quality verification considerations for research-grade material; reconstitution and handling; stack-interaction considerations; the adverse-event and safety signal across hepatic, cardiovascular, endocrine, and estrogenic domains; and a comparative assessment of five alternative anabolic-androgenic steroids (testosterone, oxandrolone, oxymetholone, stanozolol, nandrolone decanoate) against metandienone on five competency standards (oral bioavailability, anabolic efficacy, hepatotoxicity profile, estrogenic burden, and overall risk-benefit in research contexts).